Antisense Technology
Research reports on antisense technology from University of Buenos Aires provide new insights
Published in Gene Therapy Weekly, April 2nd, 2009
"Dystrophin gene multiplex polymerase chain reaction and multiplex ligation-dependant probe amplification analysis showed that both males carried an in-frame deletion of exons 45-55. Segregation analysis revealed two additional asymptomatic boys in this family," wrote V. Ferreiro and colleagues, University of Buenos Aires.
The researchers concluded: "Our finding supports previous predictions that exons 45-55 are the optimal multiexon skipping target in antisense gene...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2009-04-02)
More Articles from Gene Therapy Weekly
- Apoptosis
Study findings from H. Noguchi et al broaden understanding of apoptosis - Breast Cancer
New hormones research from Michigan State University discussed - Breast Cancer
Reports outline breast cancer study results from University of Wisconsin - Cancer Gene Therapy
Investigators at Sichuan University zero in on cancer gene therapy - Cancer Gene Therapy
Reports on cancer gene therapy findings from Yale University, Medical Department provide new insights - Cancer Gene Therapy
Studies from F. Mori et al in the area of cancer gene therapy described - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
